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Small-molecule MDM2-p53 inhibitors - recent advances 
Bian Zhang, Bernard T. Golding, Ian R. Hardcastle 
Newcastle Cancer Centre, School of Chemistry, Bedson Building, Newcastle University, NE1 7RU 
Defined Keywords 
p53 the tumour suppressor protein p53, a signalling node in the cellular stress 
and DNA damage response 
MDM2   Mouse double minute 2 protein, an E3 ligase and negative regulator of p53 
Nutlins   A series of imidazoline based MDM2-p53 inhibitors, including RG7112 
Spirooxindoles  A series of MDM2-p53 inhibitors, including SAR405838 
Cyanopyrrolidines A series of MDM2-p53 inhibitors, including RG7388 
Piperidinones  A series of MDM2-p53 inhibitors, including AMG232 
Abstract 
Potent and selective small-molecule inhibitors of the p53-MDM2 interaction intended for the 
treatment of p53 wild type tumours have designed and optimised in a number of chemical series. 
This review details recent disclosures of compounds in advanced optimisation and features key 
series that have given rise to clinical trial candidates. The structure-activity relationships for inhibitor 
classes are discussed with reference to X-ray structures, and common structural features are 
identified. 
Introduction 
The TP53 gene encodes a 53 KDa protein – the tumour suppressor p53,[1] which acts as a 
node in cell signalling, becoming activated following posttranslational modifications such as 
phosphorylation and acetylation.[2] Activated p53 transcribes a number of genes, the cognate 
proteins of which are involved in DNA repair, senescence and apoptosis.[3] The oncoprotein MDM2, 
first found to be associated with p53 protein in human sarcomas, is another product of p53 
transcription.[4,5] MDM2 inhibits the activity of p53 directly, by binding to the p53 transactivation 
domain and by acting as an E3-ubiquitin ligase, tagging the complex for proteasomal 
degradation.[6,7] MDM2 is a transcribed by activated p53, so the two proteins are linked in an 
autoregulatory feedback loop (Figure 1). Gene amplification of MDM2 giving rise to overexpression 
Future Medicinal Chemistry 2014 MDM2-p53 inhibitors 
 
2 
of MDM2 protein has been observed in tumour samples taken from common sporadic cancers. 
Overall, around 50% of tumours are p53 wild type and 10% of tumours have MDM2 amplification, 
with the highest incidence found in hepatocellular carcinoma (44%), lung (15%), sarcomas and 
osteosarcomas (28%), and Hodgkin disease (67%).[8] 
 
Figure 1: Cell signalling pathways regulating p53 and MDM2. 
The tractability of the MDM2-p53 protein-protein interaction (PPI) to inhibition by small 
molecules was first demonstrated by experiments with peptide libraries.[9,10] A peptide that 
structurally corresponded to the p53 transactivation domain showed modest inhibitory activity. This 
strategy resulted in the identification of the potent 8-mer AP peptide (IC50 = 5 nM).[11] The X-ray 
structure of an 11-mer peptide bound to MDM2 (pdb: 1YCR, Figure 8) showed that this p53-like α-
helical peptide binds to MDM2 in a deep groove lined with hydrophobic residues.[12] Three 
lipophilic p53 residues (Phe19, Trp23, and Leu26) bind deep within the groove. Two hydrogen bonds 
are formed between the Gln72 side chain of MDM2 and the backbone amide of Phe19 and between 
the backbone carbonyl of Leu54 from MDM2 and the p53 Trp23 indole NH. Overall, the relative 
small size and cavity-like shape of the binding site on MDM2 are characteristics favourable for 
insertion of small-molecule inhibitors. 
p53 
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The therapeutic hypothesis for disruption of the MDM2-p53 interaction with small-
molecules is that potent inhibition will result in the release of p53 from MDM2 inactivation. In 
tumours, free p53 is proposed to sense pre-existing DNA-damage or oncogenic signalling resulting in 
apoptosis. In normal cells, p53 activation can result in activation of non-apoptotic pathways such as 
DNA-repair and senesence.  
A number of previous reviews have described the development of inhibitor chemotypes, 
including isoindolinones discovered in our laboratory.[13-16] This review will focus on recently 
disclosed inhibitors and, in particular, the development of the series that have recently entered 
clinical trials. These first generation MDM2-p53 clinical trial candidates each demonstrate excellent 
potency and their X-ray co-crystal structures allow a detailed appraisal of structure-activity 
relationships. To date, whilst only one clinical trial has been published in full (RG7112) [17], the 
results of other trials are eagerly awaited.    
Nutlin analogues 
The cis-imidazoline class of inhibitors dubbed ‘Nutlins’, gave the first reported X-ray structure of 
MDM2 bound to a small-molecule ligand (Nutlin-2, 1a) and the first in vivo anti-tumour activity 
(Nutlin-3a, 1b).[18] The potency and selectivity of 1b has made it the tool compound of choice for 
many studies investigating the role of MDM2 and p53 in cells. Further development of the series 
sought to improve the pharmacological profile of the inhibitors, whilst retaining potency and cellular 
selectivity for p53 wild-type over mutant cell-lines.[19] In particular, metabolic liabilities at the 
imidazoline heterocycle and the 4-methoxy group were addressed by the introduction of two cis-
methyl groups, and replacement with a tert-butyl group, respectively, giving 2a, that retained similar 
potency to 1b (Table 1). Additional potency was gained by modifying the hydrophilic side-chain and 
the pharmacokinetic (PK) profile was modulated (2b-f). The X-ray co-crystal structure of MDM2 with 
2c (pdb 4IPF, Figure 8) showed the same binding mode as with 1a with the methylsulfone side chain 
making no additional interactions with the protein. Compound 2c (RG7112) was chosen as having 
the optimal profile for progression to clinical trials .[20] 




Figure 2: Chemical structures of Nutlin-2 (1a) and Nutlin-3a (1b). 







t1/2 (h)b Ref 
1a - 0.14c N/A N/A [18] 
1b - 0.09 N/A N/A [18] 
2a 
 
0.052 N/A N/A [19] 
2b 
 
0.023 64.9 2.4 [19] 
2c 
 
0.018 251.2 8.8 [19] 
2d 
 
0.033 136.5 2.3 [19] 
2e 
 
0.014 8.3 4.7 [19] 
2f 
 
0.018 N/A N/A [19] 
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a) Homogeneous time-resolved fluorescence (HTRF) assay; b) Mouse PK, single dose 50 mg/kg ; 
c) Measured as racemate 
 A series dihydroimidazothiazole derivatives 3 was developed using knowledge from the 
Nutlins. The introduction of the bicyclic unit allows the 3-isopropyl group to be fixed in the 
optimum position for access to the Phe19 pocket, which is occupied by the ethoxy group of 
2c.[21] The addition of a 6-methyl group to the ring gave 3b, with similar potency to Nutlin 1b. 
Further elaboration of the 4 position amide gave additional potency, e.g. 3d (Table 2).[22] 
Analysis of the X-ray structure of 3d bound to MDM2 showed that the amide side-chain binds 
into a groove on the surface of the protein that is formed by the movement of a flexible loop 
region. The authors posit that the pyrrolidine-2-carboxamide substituent offers the ability to 
modulate the pharmacological properties of the compounds, e.g. 3e.  
Table 2: MDM2-p53 inhibitory activity for dihydroimidazothiazoles 3.[21] 
 
 
















a) ELISA assay 
Spirooxindole Series 
The spirooxindole series, e.g. MI-63 (4a), was discovered by computational substructure searching 
for tryptophan mimetics.[23] Elaboration of the amide group and addition of a 5-fluoro group led to 
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4b, which has low nanomolar affinity for MDM2 and showed in vivo anti-tumour activity.[24] 
Importantly, 4b was found to epimerise in solution in the presence of cerium (IV) ammonium nitrate 
to a mixture of stereoisomers including 5a, which displayed improved affinity for MDM2.[25] With 
this in mind, an additional series of amide derivatives with the more stable stereochemistry was 
prepared using 3-aminocycloalkanols (Table 3).[26] A number of compounds (5b-g) were identified 
with good cell free and cellular potency. In particular, SAR405838 (5b) displayed excellent MDM2 
binding affinity and growth inhibitory activity. The X-ray co-crystal structure of 5b bound to MDM2 
showed the amide side-chain carbonyl group makes a hydrogen bond to His96, and refolding of the 
MDM2 N-terminus was observed. The PK properties of 5b-g profiled in vitro using mouse, rat and 
human liver microsomes, consequently 5b was selected for in vivo evaluation. Pharmacodynamics 
(PD) were studied by Western blotting of tumour extracts, probing for p53 and apoptotic markers, 
i.e. cleaved PARP and caspase. Importantly, a 100 mg/kg single oral dose of 5b induced complete 
tumour regression in SJSA-1 mouse xenografts, resulting in the selection of SAR405838 (5b) as the 
clinical candidate from the spirooxindole series. 
       
Figure 3: Chemical structures of MI-63 (4a) and MI-219 (4b) 
  
Future Medicinal Chemistry 2014 MDM2-p53 inhibitors 
 
7 
Table 3: MDM2-p53 inhibitory activity and growth inhibitory activity of spirooxindoles 4b and 5 
 
Compound R MDM2 Ki (nM)a 
SJSA-1 cell line 
IC50 (M) 
4b - 10.5 ± 2.0 0.95 ± 0.16b 
5a 
 




0.88 ± 0.18 0.09 ± 0.02 
5c 
 
0.61 ± 0.10 0.24 ± 0.05 
5d 
 
0.62 ± 0.05 0.20 ± 0.02 
5e 
 
0.97 ± 0.3 0.60 ± 0.16 
5f 
 
0.44 ± 0.22 0.08 ± 0.02 
5g 
 
0.62 ± 0.19 0.25 ± 0.04 
a) Fluorescence polarisation assay; b) 48 h incubation 
RG7388 series 
The Roche group sought to address the stereochemical and conformational complexities 
encountered with the spirooxindole series by replacement of the spirocyclic amide with the simpler 
and more flexible cyanopyrrolidine core (6, Table 4).[27] The cyanopyrrolidine 6a bearing similar 
substituents to MI-219 (4b), showed good MDM2 binding affinity and modest cellular activity. 
Introduction of a fluoro substituent at the 2-position of each phenyl ring was found to improve 
binding to MDM2 (6b), but both compounds showed poor oral bioavailability and rapid clearance in 
mice. Modifications to the amide side chain were introduced to improve the PK profile and remove a 
possible metabolic hot-spot. Interestingly, these modifications also had a significant effect on the 
cellular potency of the compounds, and a 4-benzenecarboxylic moiety gave improved PK and cellular 
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potency, e.g. 6c. Further optimisation focussed on the introduction of groups with distinct electronic 
properties, i.e. methoxy and fluoro, at the 2- and 3-positions (6d-g). The introduction of an ortho-
methoxy group, 6g (RG7388), gave improved MDM2 binding affinity, cellular potency and selectivity. 
Compound 6g showed in vivo activity in an SJSA-1 xenograft model, and achieved complete tumour 
regression at the 25 mg/kg dose, with a favourable PK profile. RG7388 (6g) was selected as a second 
generation MDM2-p53 clinical trial candidate owing to its improved potency, cellular selectivity and 
PK properties over RG7112 (2g) . 
Table 4: MDM2-p53 inhibitory activity and growth inhibitory activity of cyanopyrroles 6 
 











196 2.8 52.9 0.44 6.2 
6b F 
 
74 2.1 51.7 0.52 3.6 
6c F 
 
22 0.11 13.8 4.34 83 
6d F 
 
20 0.07 21.8 4.8 56 
6e F 
 
21 0.21 18.4 4.4 49 
6f F 
 





6 0.03 10.3 1.6 80 
a) HTRF assay; b) Average GI50 for SJSA-1, RKO, and HCT-116 lines (p53wt); c) oral bioavailability 
In an alternative approach, starting from the oxindole (7), a de-novo design hit, structure-based 
design suggested a spirooxindole scaffold similar to 5.[28] Structural features taken from 6b were 
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incorporated into the new scaffold giving RG8994 (8), which exhibited excellent MDM2 binding 
affinity, cellular activity, and PK profile, comparable with 6b. Compound 8 showed impressive in vivo 
activity in an SJSA-1 xenograft model, inducing tumour regression with 6.25 mg/kg daily dosing. 
Further investigations from RG8994 (8) focussed on bioisosteric replacement of the oxindole ring 
with 5- and 6-membered heterocycles.[29] Key examples RO2468 (9) and RO5353 (10) showed 
excellent MDM2 binding affinity (IC50 = 6 and 7 nM, respectively) and impressive cellular activity and 
selectivity (GI50 = 15 and 7 nM, respectively). Both compounds presented excellent mouse PK 
properties, and showed tumour regression in SJSA-1 xenografts at 10 mg/kg daily dosing. 
 
Figure 4: Schematic for the design evolution of spirooxindoles 8-10. 
A series of imidazole-based MDM2 inhibitors was designed by close examination of a model of the 
AP peptide bound to MDM2.[30] The imidazole scaffold was chosen to orientate the three 
substituents into the Phe19, Trp23, and Leu26 pockets, and to make favourable contacts with Val23. 
Initial examples, e.g. 11, had modest inhibitory activity for MDM2. Addition of a hydrophilic group to 
the indole via a carboxamide link (12) gave a significant improvement in activity. Analysis of the X-
ray co-crystal structure of MDM2 with 12 revealed that the carbonyl group makes water-bridged 
hydrogen bonds to the protein, whereas the morpholino group projects into solvent. Development 
of this series sought to take advantage of a possible interaction with His96, observed to stack 
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favourably with the chlorobenzyl group of 12.[31] Introduction of an amide group at the 2-position 
of the imidazole, replacement of the 4-chlorobenzyl group with a 3-chlorophenyl substituent and 
simplification of the indole substituent to a 3-chlorophenyl group led to 13a, which showed 
moderate MDM2-p53 inhibitory activity (Table 5). The corresponding acid 13b showed improved 
activity. Modelling indicated that additional substitution on the aromatic rings would induce the 
ideal conformation for binding, as was demonstrated by the difluoro compound 13d with excellent 
inhibitory activity. A further gain in potency was achieved by the replacement of the 5-phenyl 
substituent with a cyclohexyl group (13e),thus optimising interactions in the Phe19 pocket. The 
cellular activity was optimised by replacement of the carboxylic acid group with bioisosteric groups 
13f-h, the oxadiazoleamine 13h showing the best cellular activity. The presence of a tert-
butylacetamide group at R1, as in 13i, conferred the best combination of inhibitory activity and 
cellular activity. The latter property in this series is low compared with other series displaying low 
nanomolar potency in cell-free MDM2-p53 inhibition assays, possibly indicating poor cellular uptake. 
 
Figure 5: Chemical structures of imidazoles 11 and 12. 
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Table 5: MDM2-p53 inhibitory activity and growth inhibitory activity of imidazoles 13. [31] 
 






13a H H Ph -CONHCH3 H 0.31  
13b H H Ph -CO2H H 0.12 N/A 
13c  Me H 3-MePh -CO2H H 0.008 10.2 
13d H F Ph -CO2H F 0.003 14.0 
13e H F c-hexane -CO2H F 0.004 13.2 
13f H F c-hexane -CONH2 F 0.018 4.1 
13g H F c-hexane 
 
F 0.003 4.4 
13h H F c-hexane 
 





F 0.002 0.5 
a) Time-resolved Förster resonance energy transfer (TR-FRET) assay 
The substituted piperidines 14a and 14b were identified as hits with micromolar potency by a 
screening campaign at Merck using a MDM2-p53 fluorescence polarisation (FP) assay.[32] 
Optimisation of the piperazine amide moiety showed that replacement of the pyridine nitrogen with 
an alkoxy substituent gave improved potency, and the 2-methoxyethoxy substituent was taken into 
the next round of SAR (14c, Table 6). The DMPK profile of the series was addressed by the addition 
of substituents at the 2-position of the piperidine ring.[33] This modification had the additional 
advantage of favouring the bound conformation of the ring, resulting in additional potency: e.g., the 
2-allyl derivative 14d showed a 4-fold improvement in cell-free and cellular potency over 14c. 
Additional polarity was introduced by dihydroxylation of 14a as in 14f. In this case, the more potent 
diastereoisomer showed improved potency and cellular activity against p53wt cell lines. 
Simplification of the substituent to 2-hydroxyethyl, as in 14g, gave a modest improvement in 
potency and cellular activity. 




Figure 6: Chemical structures and MDM2 inhibitory activities of piperidines 14a and 14b. 
Table 6: MDM2-p53 inhibitory activity and growth inhibitory activity of substituted piperazines 14. 
[32] 
 
Compound R IC50 (nM)a SJSA-1 IC50 (M) 
14c H 169 4.7 
14d  41 1 




14g  24 0.53 
a) FP assay 
Analysis of the X-ray structures of a number of MDM2 inhibitory chemotype by the Amgen group 
pointed to the importance of interactions with His96, which forms part of the Leu23 pocket, leading 
to improved potency, in addition to efficient occupation of the three hydrophobic pockets on MDM2 
by the ligand. On this basis, the piperidone series of inhibitors was conceived, e.g. 15a and 15b.[34] 
Molecular modelling guided SAR studies, which sought to optimise the N-alkyl group, established the 
cyclopropylmethyl group as the most potent in the series.[35] The introduction of the (3R)-carboxyl 
group at C3 resulted in a 20-fold improvement in potency (15b), whereas the (3S)-diastereomer was 
2-fold less potent. The importance of the interaction with His96 was confirmed by the loss of 
potency observed for the amide derivative 15d, and the retention of potency for the isosteric 
tetrazole 15e. Importantly, the authors noted a reduction in activity when the assays were 
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conducted in the presence of human serum, due to plasma protein binding. Guided by 
computational models, the introduction of an additional group to the R1 substituent (e.g. tert-butyl 
ester 15f) resulted in a 8-fold gain in potency, rationalised by the bulky group directing R1 into the 
optimal conformation for binding. Similarly, the introduction of a methyl group at C3 (15g) resulted 
in a 2-fold improvement in potency by stabilising the bound conformation of the piperidone ring. 
The tetrazole analogue 15h showed improved cell-free potency, but similar cellular potency. 
Enhanced cellular potency was achieved by replacing the R1 substituent with 3-(2-hydroxypentyl) 
leading to 15i (AM8553), a compound that showed promising in vivo PK and PD properties. In vivo 
efficacy was demonstrated, with tumour stasis observed on oral daily dosing at 150mg/kg, and oral 
twice daily 100 mg/kg, in an SJSA-1 mouse xenograft model. 
Table 7: MDM2-p53 inhibitory activity and growth inhibitory activity of substituted piperidones 15a-
i. [34] 
 
Compound R1 R2 R3 IC50 (nM)a 
SJSA-1 




H 34.0 ± 5.8 3.35 ± 0.38 
15b 
  
H 6c nd 
15c 
 
H H 820 ± 280 nd 
15d 
  
H 270 ± 70 nd 
15e 
  
H 14 ± 4 nd 
15f 
  
H 4.2 ± 0.9 0.476 ± 0.087 
15g 
   
2.2 ± 0.7 0.19 ± 0.06 
15h 
   
0.90 ± 0.21 0.17 ± 0.03 
15i 
(AM8553)    
1.1 ± 0.5 0.068 ± 0.016 
a) HTRF assay; b) 10% human serum added to medium; c) KD by surface plasmon resonance 
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Guided by an X-ray structure of 15i bound to MDM2 (pdb: 4ERF, Figure 8), further optimisation of 
this chemotype focussed on the N-substituent with the aim of optimising interactions in the ‘glycine 
shelf’ region (Table 8).[36] Homologation of the alcohol group (15j) resulted in a modest 
improvement in cell free potency that did not transfer to the cellular potency. In contrast, the 
cyclopropylsulfonamide derivative 15k, reversed sulfonamide 15l, and sulfone 15m (AMG 232) 
displayed improved cell-free potency and excellent growth inhibitory activity. The X-ray co-crystal 
structure of the sulfone 15n (pdb: 4OCC, Figure 8) showed the ethyl R1-group projecting into the 
Phe19 binding pocket, directed by the -substituent. The sulfone group is situated close to the Gly58 
CH suggesting a favourable interaction, accounting for the improved potency. Of the three 
modifications, the sulfone derivative showed the best stability in human hepatocytes and the lowest 
in vivo rat clearance, giving an acceptable half-life. In vivo efficacy was demonstrated with AMG 232 
(15m) with complete tumour regression in SJSA-1 xenografts seen with oral daily dose 60 mg/kg, 
leading to this compound being selected for clinical trials. 
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Table 8: MDM2-p53 and growth inhibitory activity and PK properties of substituted piperidones 15i-
n. [36] 
 









Rat PK  





1.1 ± 0.5 72 ± 14 3.0 1.2/3.5 
15j Et 
 
0.4 ± 0.08 150 ± 62 nd nd 
15k i-Pr 
 
0.2 ± 0.06 6.5 ± 3.0 7.3 3.2/2.5 
15l c-Pr 
 
0.1 ± 0.02 4.4 ± 0.66 14 6.2/1.6 
15m i-Pr 
 
0.6 ± 0.4 9.1 ± 2.8 6.3 0.66/2.4 
15n Et 
 
0.1 ± 0.04 3.0 ± 0.8 nd nd 
a) HTRF assay; b) 10% human serum added to medium; c) clearance in human hepatocytes. 
Further modifications were pursued with the aim of replacing the carboxylic acid moiety, whilst 
retaining the favourable interaction with His96 (Table 9).[37] Replacement with carboxyl-substituted 
heterocycles, e.g. 2-pyridyl derivative 15p, pyrazole 15q, and thiazoles 15r and 15s, gave equipotent 
compounds. A hydrogen bond between the His96 NH and heterocycle N was observed in the co-
crystal structures of 15p and 15s. The carboxylic acid group serves to modulate inhibition of 
cytochrome P450 monooxygenase (CYP) with the carboxymethyl derivative 15s showing the best 
profile. Compound 15s exhibited in vivo good mouse and rat PK, and activity in the SJSA-1 xenograft 
model, inducing tumour growth inhibition with oral daily dosing at 50 mg/kg. 
Table 9: MDM2-p53 and growth inhibitory activity and PK properties of substituted piperidones 15. 
[37] 












15o H Et 
 
0.10 ± 0.5 3 ± 1 N/A 
15p H c-Pr 
 
0.10 ± 0.01 5 ± 3 10 
15q H c-Pr 
 
0.10 ± 0.01 4 ± 1 2.8 
15r F c-Pr 
 
0.10 ± 0.01 4 ± 1 10.0 
15s F c-Pr 
 
0.10 ± 0.01 16 ± 1 5.5 
a) HTRF assay; b) 10% human serum added to medium; c) clearance in human hepatocytes. 
In addition to the piperidinone series, a series of related morpholinones was identified with 
acceptable potency and cellular activity e.g. 16a (Table 10).[38] Optimisation of this series was 
guided by the knowledge gained in the piperidone series.[39] Comparison of 16b with the equivalent 
piperidone showed a 5-10 fold loss of potency, but better stability in hepatocytes derived from 
human and other mammalian species. Extensive SAR studies demonstrated the potency of N-
arylsulfonamides, e.g. 16b. However, time-dependent inhibition of CYP3A4 was observed for this 
sub-series. The sulfone series retained equivalent potency, e.g. 16c, but without the CYP liability. 
Optimisation of the R1 group revealed that the N-cyclopropylmethyl compound 16d had the best 
combination of potency and low clearance in human hepatocytes. Mouse SJSA-1 xenograft 
experiments with 16d showed tumour stasis with 100 mg/kg oral daily dosing. 




Figure 7: Chemical structures of piperidinone 16a. 
Table 10: MDM2-p53 and growth inhibitory activity and PK properties of substituted morpholinones 
16b-d 
 
compound R1 R2 
HTRF IC50 
(nM)a 






Rat PK  
(iv, 0.5 mg/kg) 
CL 
(L/h/kg)/t1/2(h) 






0.3 ± 0.1 35 ± 4 < 0.1 N/A 
16c Et 
 
0.5 ± 0.3 37 ± 19 1.9 0.23/4.1 
16d c-Pr 
 
0.4 ± 0.1 25 ± 9 1.4 0.35/5.7 
a) HTRF assay; b) 10% human serum added to medium. 
Structural biology overview – common pharmacophore 
Since the publication of the X-ray structure of Nutlin-2 bound to MDM2 [12], a number of structures 
have been added to the pdb, for a range of MDM2-p53 inhibitory chemotypes. These structures 
reveal a number of common features as shown in an overlay of the core structures of the Nutlin 
RG7112 2g, a spirooxindole scaffold 5h, RG7388 6a, and piperidinone analogues of AMG 233 15i and 
15n (Figure 8A). The Trp23 pocket strongly favours a chloroaromatic group and each ligand has the 
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chlorine atom in a very similar position, occupying the lipophilic base of the pocket. The Leu26 is also 
occupied by a chloroaromatic group, with the chlorine atoms in each structure occuping a similar 
space and vector. The phenyl rings also occupy similar space regardless of the vector to the scaffold. 
The greatest structural diversity is seen in the Phe19 pocket that is filled by a saturated alkyl group, 
e.g. tert-butyl, in the structures shown. The His96 is seen to make favourable interactions with the 
carboxylic acid or carboxamide groups of the ligands, where present. Each scaffold bears a 
hydrophilic group, which occupies the glycine shelf for RG7388 analogue 6a and piperidone 15i, or 
overlay the Phe pocket for RG7112 2g, and project into solvent. The interactions for each ligand are 
summarised in Figure 9. 
A:  B:  C:  
D:  E:  F:  
Figure 8: A: Overlay of MDM2-ligand complex X-ray crystal structures; B: 1YCR – p53 peptide (grey 
and magenta); C: 4IPF – RG7112 2g (magenta), D: 3LBL – spirooxindole scaffold 5h (light blue); E: 
4JRG – RG7388 analogue 6a (green); F: 4ERF and 4OCC – AMG-232 analogues 15i (pale brown) and 




His96 His96 His96 
Gly shelf 




Figure 9: Schematic showing the occupancy of the MDM2 Phe19, Trp23, and Leu26 binding pockets 
by ligands 2g, 5h, 6a, and 15i.  
Clinical Trials 
The first full publication of a phase 1 clinical trial of an MDM2-p53 inhibitor detailed the activity of 
RG7112 2g in liposarcoma patients.[17] Patients received RG7112 2g (1440 mg/m² per day, oral 
dosing) for 10 days in up to three 28-day cycles. Within the group, 18 from 20 patients had TP53 
wild-type tumours and two carried missense TP53 mutations. Among the patients assessed, 14 from 
17 had MDM2 gene amplification. An initial response to therapy was observed in 16 from 20 
patients as partial response or stable disease. Interpatient variability in pharmacokinetics allowed a 
linear relationship to be established between drug exposure and the PD markers TUNEL (for 
apoptosis) and MIC-1 (for p53 activation). Some toxicity was observed including neutropenia and 
thrombocytopenia, thought to be related to p53 activation. The poor PK profile of the Nutlin 
analogue RG7112 2g can be predicted from the compound’s high molecular weight (MW) and 
lipophilicity. The follow-up compound RG7388 6g currently in trials has lower MW and lipophilicity 
and has replaced 2g in clinical studies.   




To date at least seven chemically diverse MDM2-p53 inhibitors are in Phase I or Phase II clinical trials 
for the treatment of solid and haematological malignancies. Also, a number of combination studies 
with chemotherapy and targeted agents are running concurrently. Twenty years have elapsed 
between the initial characterisation of MDM2 in 1992[4] and the first clinical data from a small 
molecule inhibitor. The data are encouraging and suggest that MDM2-p53 inhibition can be a useful 
therapy for p53 wild-type tumours. The data also reinforce the challenges of designing an inhibitor 
of a lipophilic protein-protein interaction, whilst retaining favourable pharmaceutical properties. 
Given the range of chemotypes reported, it is likely that one or more MDM2-p53 inhibitor will be 
successful in the near future.  
Executive Summary 
 Overexpression of MDM2 functionally inactivates p53 in p53 wild-type tumours. 
 Inhibition of MDM2-p53 protein-protein interaction results in activation of p53 in cells 
 The MDM2-p53 protein-protein interaction is a well validated and attractive target for 
small-molecule therapeutics 
 A number of series of MDM2-p53 inhibitors have been discovered, based on different 
chemotypes. Potency and in vivo efficacy have been demonstrated for compounds with 
acceptable pharmaceutical properties. 
 MDM2-p53 inhibitors have entered clinical trials in solid and haematological malignancies 
as single agents and in combination with targeted agents 
 RG7112 showed promising activity in a Phase 1 trial, but interpatent variablity in 
pharmacokinetics was observed 
Key Terms 
p53 - the tumour suppressor protein p53, a transcription factor 
MDM2 - Mouse Double Minute 2, an E3 ligase, transcriptional target for p53 
Protein-protein interaction - the surface to surface interaction of two proteins that may include sites 
able to bind small molecules 
SJSA-1 - osteosarcoma tumour cell-line that is MDM2 amplified and p53 wild type, used for in vitro 
cell assays and xenograft models 
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